Ziopharm Oncology reported $-22639000 in Operating Profit for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Amgen AMGN:US $ 828M 1301M
Arena Pharmaceuticals ARNA:US $ -144.39M 12.4M
AstraZeneca AZN:LN 1.13B 768M
Baxter International BAX:US $ 424M 34M
Biogen BIIB:US $ 794M 308.3M
Bristol Myers Squibb BMY:US $ 1715M 36M
Corcept Therapeutics CORT:US $ 31.94M 12.3M
Curis CRIS:US $ -10.65M 1.85M
Eleven Biotherapeutics EBIO:US -25399000 29.82M
Gilead Sciences GILD:US $ 2246M 644M
GlaxoSmithKline GSK:LN 1.68B 18M
Immunogen IMGN:US $ -27.37M 1.55M
Intercept Pharmaceuticals ICPT:US $ 0.76M 30.11M
Intrexon XON:US $ -15.67M 2.01M
Johnson & Johnson JNJ:US $ 3849M 2813M
Karyopharm Therapeutics KPTI:US $ -49048000 3.32M
Merk MRK:US $ 1497M 1517M
Novartis NOVN:VX 3.48B 1.06B
Pfizer PFE:US $ 5914M 397M
Ptc Therapeutics PTCT:US $ -98.49M 0.34M
Regeneron Pharmaceuticals REGN:US $ 3347.2M 2234.5M
Sangamo Biosciences SGMO:US $ -48.7M 2.4M
Tg Therapeutics TGTX:US $ -77.49M 11.71M
Verastem VSTM:US $ -15.94M 1.84M
YTE INCY:US $ 140.84M 42.04M
Ziopharm Oncology ZIOP:US $ -22639000 1.08M